ANX-007 is a monoclonal antibody commercialized by Annexon, with a leading Phase II program in Geographic Atrophy. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of ANX-007’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ANX-007 is expected to reach an annual total of $7 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ANX-007 is under development for the treatment of open-angle glaucoma and geographic atrophy. The therapeutic candidate is administered through intravitreal route. It is developed based on classical complement pathway. The therapeutic candidate acts by targeting C1q.
Annexon is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates include ANX005 and ANX007, which are potent inhibitory antibodies against C1q, an initiating molecule of the classical complement cascade. The company also develops ANX105, for the treatment of neurodegenerative disorders. It develops therapeutic products to protect against synapse loss and inflammatory nerve damage in the brain and retinal cells. Annexon is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$145.6 million in FY2022, compared to an operating loss of US$130.7 million in FY2021. The net loss of the company was US$142 million in FY2022, compared to a net loss of US$130.3 million in FY2021.
For a complete picture of ANX-007’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.